The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...
In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...
Chicago, USA-based Emalex Biosciences announced positive top-line data from its Phase III registrational study of ecopipam, a ...
Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...
Medpage Today on MSN12h
'Banned' Words at CDC? House Passes Budget Bill; Measles Outbreak in Texas ExpandsCDC staff received an email this week telling them to avoid using more than a dozen terms or words -- including "health ...
Neurodevelopmental disorders company GRIN Therapeutics, an affiliate of the Blackstone Life Sciences portfolio company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback